Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$16.35M$16.35M— vs Q3 2023 Net Income-$85.58M-$85.58MN/M vs Q3 2023 EPS Diluted-$1.32-$1.32N/M vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flowderived-$63,573,000N/M Free Cash Flowderived-$63,617,000N/M Margins · derivedGross margin85.6%
Operating margin-433.0%
Net margin-523.3%
ended Sep 30, 2024 · filed Nov 7, 2024 · 38 d after period end